Similar articles

• Genital ulcer disease treatment policies and access to acyclovir in eight sub-Saharan African countries.

  Corbell C, Stergachis A, Ndowa F, Ndase P, Barnes L, Celum C. Corbell C, et al. Sex Transm Dis. 2010 Aug;37(8):488-93. doi: 10.1097/OLQ.0b013e3181e212e5. Sex Transm Dis. 2010. PMID: 20539260
• Genital ulcer disease treatment policies and herpes.

  O'Farrell N, Moodley P. O'Farrell N, et al. Sex Transm Dis. 2011 Feb;38(2):150. doi: 10.1097/OLQ.0b013e318205432b. Sex Transm Dis. 2011. PMID: 21209599 No abstract available.
• Short-course therapy for recurrent genital herpes and herpes labialis.

  Spruance S, Aoki FY, Tyring S, Stanberry L, Whitley R, Hamed K. Spruance S, et al. J Fam Pract. 2007 Jan;56(1):30-6. J Fam Pract. 2007. PMID: 17217895 Review. No abstract available.
• Efficacy of topical acyclovir monophosphate, acyclovir, or penciclovir in orofacial HSV-1 infections of mice and genital HSV-2 infections of guinea pigs.

  Kern ER, Palmer J, Szczech G, Painter G, Hostetler KY. Kern ER, et al. Nucleosides Nucleotides Nucleic Acids. 2000 Jan-Feb;19(1-2):501-13. doi: 10.1080/15257770008033024. Nucleosides Nucleotides Nucleic Acids. 2000. PMID: 10772730
• An update on short-course episodic and prevention therapies for herpes genitalis.

  Corey L, Bodsworth N, Mindel A, Patel R, Schacker T, Stanberry L. Corey L, et al. Herpes. 2007 Jun;14 Suppl 1:5A-11A. Herpes. 2007. PMID: 17877886 Review.